To include your compound in the COVID-19 Resource Center, submit it here.

Aclasta regulatory update

EMA's CHMP said labels of all bisphosphonate-containing medicines approved to treat and prevent bone disorders should be updated to include a warning on the risk of atypical femoral fractures. The

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE